Tag: FDA biosimilars

lot-to-lot variability biosimilars biologics FDA biosimilars biological drug variation

Lot-to-Lot Variability in Biologics and Biosimilars: What You Need to Know

Lot-to-lot variability is natural in biologics and biosimilars due to their complex manufacturing. Learn how regulators ensure safety despite molecular differences, why biosimilars aren't generics, and what this means for patients and labs.

November 23 2025